Insmed Incorporated (NASDAQ: INSM) will announce results from its U.S. phase 2 clinical trial of ARIKAYCE™, or liposomal amikacin for inhalation, to treat nontuberculous mycobacteria (NTM) lung infections on Wednesday, March 26, 2014 at approximately 7:00 a.m. Eastern time
Now,,who in their right minds would ask everyone to watch them look stupid? I have to believe the
news is either good, or their going to make it look good...If it where bad, they would have announced
after the market closed today....just my take...what say you?
They announced distinctly non-exciting news before the bell last time for the CF study, and the market totally tanked in that instance.
I hope that doesn't happen to you this time.
Either way, strap in - it will be interesting.